Abiopharma

🔍 Appelhans Dannielle (Director)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 1,161 shares of Restricted Stock Units (Direct)
  Date: 2026-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,161.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,778 shares of Option to Purchase Common Stock at $107.72 per share (Derivative)
  Date: 2026-09-01 | Code: A | Expires: 2036-09-01 | equity_swap_involved: 0 | shares_owned_after: 1,778.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
• F2: Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.